Text Size

A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

This study has been completed.
Sponsor:
Collaborator:
Chinese Academy of Sciences
Information provided by:
Kunming Medical University
ClinicalTrials.gov Identifier:
NCT00703742
First received: June 20, 2008
Last updated: June 24, 2011
Last verified: June 2011
History of Changes

June 20, 2008
June 24, 2011
June 2008
June 2011   (final data collection date for primary outcome measure)
change of fMRI after medication [ Time Frame: baseline, 4 weeks, 8 weeks ] [ Designated as safety issue: Yes ]
change of fMRI after medication [ Time Frame: baseline, 4w.8w ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00703742 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression
A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

The purpose of this study is:

  1. to find out the structural or functional effects of selective serotonin reuptake inhibitors (SSRI) in major depressive disorder (MDD);
  2. find special abnormalities in depression secondary to other disease, e.g., autoimmune disease like systemic lupus erythematosus (SLE).
  3. find the relationship between the efficacy of antidepressant and the change of neuroimaging in MDD
  4. to find possible predispose to MDD
  5. to explore the DNA methylation status in depression;
  1. to explore the pathology of depression
  2. to identify the difference between MDD and depression secondary to other disease ,especially autoimmune disease
  3. to explore the effect of gene-environment interaction on the epigenetic regulation of the depression
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Health Services Research
  • Depression
  • Depression Secondary to Other Disease
Drug: Escitalopram
A,1: Escitalopram, oral, 20 mg/day, 8 weeks
Experimental: A,1
A: Escitalopram, 20 mg/day,8weeks
Intervention: Drug: Escitalopram
Xu J, Cheng Y, Chai P, Lu Z, Li H, Luo C, Li X, Li L, Zhou Q, Chen B, Cao J, Xu X, Shan B, Xu L, Wen J. White-matter volume reduction and the protective effect of immunosuppressive therapy in systemic lupus erythematosus patients with normal appearance by conventional magnetic resonance imaging. J Rheumatol. 2010 May;37(5):974-86. Epub 2010 Mar 15.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
June 2011
June 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • DSM-IV Major Depression or Dysthymia
  • Age 18-65
  • Physically healthy
  • Drug-free

Exclusion Criteria:

  • Body metal (e.g., wire stitches, screws in bones, stainless steel hips)
  • History of Psychosis or Epilepsy
  • Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)
  • Bipolar I
  • Need for wash-out from effective treatment in order to participate
  • Pregnant
  • High suicide risk
  • Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants
Both
18 Years to 70 Years
Yes
Contact information is only displayed when the study is recruiting subjects
China
 
NCT00703742
Kunming MC
Yes
Kunming Medical College
Kunming Medical University
Chinese Academy of Sciences
Study Director: Xu Xiufeng Kunming Medical University
Kunming Medical University
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP